Jounce Therapeutics Profile

USD 0.79  4.23%

Exercise or conversion by Barbara Duncan of 2000 shares of Jounce Therapeutics subject to Rule 16b-3

Jounce Therapeutics Inc insider trading alert for exercise of stock option (right to buy) by Barbara Duncan, the corporate stakeholder, on March 19, 2018. This event was filed by Jounce Therapeutics Inc with SEC on 2018-03-19. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Jounce Therapeutics Summary

Jounce Therapeutics (JNCE) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 112 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 631.73 M. Jounce Therapeutics has 32.46 M outstanding shares of which 3.27 M shares are currently shorted by private and institutional investors with about 24.78 trading days to cover. The company currently holds about 235.65 M in cash with (90.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.
Check Jounce Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 10.7%30 days 19.46  about 89.24%
Based on normal probability distribution, the odds of Jounce Therapeutics to move above current price in 30 days from now is about 89.24% (This Jounce Therapeutics probability density function shows the probability of Jounce Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Trv Gp Ii LlcCommon Shares10.2 M228.6 M
Trv Gp Iii LlcCommon Shares3 M68.1 M
View Jounce Therapeutics Diagnostics

Selected Jounce Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Jounce Therapeutics Against Markets

Current Ratings

Jounce Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 49% 
Equity ratings for Jounce Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics is traded on NASDAQ in USA. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameJounce Therapeutics
President CEO, DirectorRichard MurrayView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address780 Memorial Drive
CIK Number01640455.0
IndustryPharmaceutical Products
Contact Number857 259 3840
CurrencyUSD - US Dollar


Jounce Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
30.0Strong Buy3Odds
Jounce Therapeutics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Jounce Therapeutics Analyst Advice  


Jounce Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.25November 8, 2017
Jounce Therapeutics normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Jounce Therapeutics Corporate Directors
Barbara Duncan Independent Director, MBA
Luis Diaz Director
Robert Kamen Independent Director, Ph.D
Please also check Risk vs Return Analysis. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.